Ozolins and Kakhniuk Suspended After Positive Drug Tests

Regulatory Oversight and the San Jose Samples

In the quiet, often overlooked corridors of the ITF World Tennis Tour, the shadow of anti-doping regulation has fallen heavily. The International Tennis Integrity Agency (ITIA) confirmed that Karlis Ozolins, ranked No. 546, and Daniil Kakhniuk, ranked No. 1,123, have been issued provisional suspensions. The sanctions stem from mandatory testing conducted at a tournament held in San Jose, Costa Rica, during the month of February.

Both athletes tested positive for clostebol, a prohibited anabolic agent. According to official records, the suspensions were formally enacted on April 14. In the high-stakes environment of professional tennis, where every point is a fight for survival, these players now face the unforgiving reality of a forced hiatus from the ATP rankings and competitive play.

The Path of Due Process and Legal Support

As the tennis community absorbs the news, the procedural gears of the ITIA are already in motion. Neither Ozolins nor Kakhniuk has moved to contest their provisional status as of the announcement date, leaving their competitive future in a state of indefinite suspension. The mental grind of a professional career is difficult enough without the added weight of an anti-doping investigation.

To ensure procedural integrity, the ITIA has confirmed that both players are being granted access to pro-bono legal counsel and independent wellbeing support. It is a stark reminder that behind the statistics and the pursuit of a tour breakthrough, players are subject to a global framework of compliance that permits no errors. For these two, the focus has shifted from winning matches to navigating a complex legal and regulatory landscape.